These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 23427864

  • 1. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
    Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P.
    Diabetes Technol Ther; 2013 Mar; 15(3):214-22. PubMed ID: 23427864
    [Abstract] [Full Text] [Related]

  • 2. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
    Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P.
    Diabet Med; 2013 Jul; 30(7):846-54. PubMed ID: 23413771
    [Abstract] [Full Text] [Related]

  • 3. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [Abstract] [Full Text] [Related]

  • 4. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [Abstract] [Full Text] [Related]

  • 5. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 6. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
    Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P.
    Intern Med; 2013 Jun; 52(19):2179-87. PubMed ID: 24088749
    [Abstract] [Full Text] [Related]

  • 7. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
    Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [Abstract] [Full Text] [Related]

  • 9. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K.
    Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P.
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group.
    Lancet; 2010 Aug 07; 376(9739):431-9. PubMed ID: 20580422
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct 07; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.
    Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P.
    Expert Opin Pharmacother; 2012 Dec 07; 13(17):2433-42. PubMed ID: 23061989
    [Abstract] [Full Text] [Related]

  • 14. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
    Hanefeld M, Pfützner A, Forst T, Lübben G.
    Curr Med Res Opin; 2006 Jun 07; 22(6):1211-5. PubMed ID: 16846554
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.
    Henry RR, Staels B, Fonseca VA, Chou MZ, Teng R, Golm GT, Langdon RB, Kaufman KD, Steinberg H, Goldstein BJ.
    Diabetes Obes Metab; 2014 Mar 07; 16(3):223-30. PubMed ID: 23909985
    [Abstract] [Full Text] [Related]

  • 16. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
    Koren S, Shemesh-Bar L, Tirosh A, Peleg RK, Berman S, Hamad RA, Vinker S, Golik A, Efrati S.
    Diabetes Technol Ther; 2012 Jul 07; 14(7):561-7. PubMed ID: 22512265
    [Abstract] [Full Text] [Related]

  • 17. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M, Ahrén B, Inzucchi SE, Guan Y, Mallick M, Xu L, O'Neill EA, Williams-Herman DE, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2013 Dec 07; 15(12):1101-10. PubMed ID: 23782502
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
    Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.
    J Assoc Physicians India; 2003 Nov 07; 51():1061-4. PubMed ID: 15260389
    [Abstract] [Full Text] [Related]

  • 19. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
    Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H.
    Int J Clin Pract; 2011 Feb 07; 65(2):154-64. PubMed ID: 21235696
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.
    Curr Med Res Opin; 2009 Mar 07; 25(3):569-83. PubMed ID: 19232032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.